USAQ Revenue Jumps 32%, But Soaring Costs Drive Net Loss

Ticker: USAQ · Form: 10-Q · Filed: Nov 13, 2025 · CIK: 856984

Sentiment: bearish

Topics: Healthcare Technology, SaaS, Going Concern, Net Loss, Revenue Growth, Interest Expense, 10-Q Filing

TL;DR

**USAQ's revenue growth is overshadowed by ballooning expenses and a net loss, making it a risky bet despite market expansion.**

AI Summary

QHSLab, Inc. (USAQ) reported a mixed financial performance for the nine months ended September 30, 2025. Revenue increased significantly to $1,987,931, up from $1,505,945 in the prior year period, representing a 32% increase. Gross profit also rose to $1,322,590 from $945,736. However, the company posted a net loss of $99,156 for the nine-month period, a notable decline from a net income of $28,350 in the same period of 2024. This loss was primarily driven by a substantial increase in interest expense, which more than doubled to $194,894 from $104,311, and higher operating expenses, including a 97% increase in research and development to $369,166. The company continues to operate with a significant stockholders' deficit of $610,912 as of September 30, 2025, and its 'going concern' status remains in doubt due to historical losses and reliance on future financing.

Why It Matters

QHSLab's increased revenue indicates growing market penetration for its value-based healthcare solutions, which could be a positive signal for investors looking at the digital therapeutics space. However, the shift from net income to a net loss, exacerbated by rising interest expenses and R&D, raises concerns about profitability and operational efficiency. For employees, continued growth in revenue might suggest job stability, but the 'going concern' warning highlights underlying financial fragility. Customers, primarily PCPs, benefit from the company's medical device technology and SaaS offerings, but the company's financial health could impact future service reliability and innovation in a competitive healthcare technology market.

Risk Assessment

Risk Level: high — The company explicitly states 'These conditions raise substantial doubt about the Company's ability to continue as a going concern' in Note 2. This is supported by a net loss of $99,156 for the nine months ended September 30, 2025, a significant deterioration from a net income of $28,350 in the prior year. Additionally, the company has a total stockholders' deficit of $610,912, indicating accumulated losses exceeding equity.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate QHSLab's ability to secure future financing and achieve consistent profitability. Given the 'going concern' warning and increasing net losses, a 'wait and see' approach is advisable, focusing on future filings for concrete evidence of improved financial stability and reduced leverage before considering any investment.

Financial Highlights

debt To Equity
N/A
revenue
$1.99M
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$99.16K
eps
N/A
gross Margin
66.5%
cash Position
$158.39K
revenue Growth
+32%

Key Numbers

Key Players & Entities

FAQ

What is QHSLab, Inc.'s primary business focus?

QHSLab, Inc. is a medical device technology and software-as-a-service (SaaS) company. It focuses on enabling primary care physicians (PCPs) to increase revenues by providing value-based tools for evaluating and treating chronic diseases, as well as offering preventive care through reimbursable procedures.

Did QHSLab, Inc. achieve profitability in the nine months ended September 30, 2025?

No, QHSLab, Inc. reported a net loss of $99,156 for the nine months ended September 30, 2025. This contrasts with a net income of $28,350 for the same period in 2024.

What was QHSLab, Inc.'s revenue for the nine months ended September 30, 2025?

QHSLab, Inc.'s revenue for the nine months ended September 30, 2025, was $1,987,931. This represents a significant increase from $1,505,945 reported for the nine months ended September 30, 2024.

What is the 'going concern' risk for QHSLab, Inc.?

QHSLab, Inc. has incurred losses during most fiscal quarters since inception, is highly leveraged, and does not consistently generate cash from operations. These conditions, as stated in Note 2, raise substantial doubt about the Company's ability to continue as a going concern without increased positive cash flows or future equity issuances.

How did QHSLab, Inc.'s operating expenses change in the nine months ended September 30, 2025?

Total operating expenses for QHSLab, Inc. increased to $1,226,852 for the nine months ended September 30, 2025, up from $813,075 in the prior year. This was driven by increases in sales and marketing, general and administrative, and research and development expenses.

What was the interest expense for QHSLab, Inc. in the nine months ended September 30, 2025?

The interest expense for QHSLab, Inc. was $194,894 for the nine months ended September 30, 2025. This is a substantial increase from $104,311 reported for the same period in 2024.

What is QHSLab, Inc.'s current stockholders' deficit?

As of September 30, 2025, QHSLab, Inc. reported a total stockholders' deficit of $610,912. This indicates that the company's liabilities exceed its assets, reflecting accumulated losses.

How many shares of common stock did QHSLab, Inc. have outstanding on November 13, 2025?

On November 13, 2025, QHSLab, Inc. had 11,281,527 shares of common stock outstanding. This figure is consistent with the shares outstanding as of September 30, 2025.

What was the change in cash and cash equivalents for QHSLab, Inc. during the nine months ended September 30, 2025?

QHSLab, Inc.'s cash and cash equivalents increased by $1,223 during the nine months ended September 30, 2025, reaching $158,391. This was a modest increase from $157,168 at the beginning of the year.

What accounting policy change did QHSLab, Inc. implement regarding revenue recognition?

Beginning April 1, 2025, QHSLab, Inc. changed its policy for when title transitions to its customers from upon delivery to upon shipment. This change did not impact the timing of revenue recognition, which continues to be recorded when title passes to the customer.

Risk Factors

Industry Context

QHSLab, Inc. operates in a competitive landscape where innovation and efficient capital management are crucial. Companies in this sector often face pressure to invest heavily in R&D while managing operational costs and financing expenses to achieve profitability.

Regulatory Implications

As a publicly traded company, QHSLab, Inc. must adhere to SEC reporting requirements. The 'going concern' disclosure indicates potential scrutiny from regulators regarding financial stability and transparency.

What Investors Should Do

  1. Monitor R&D spend and its impact on future revenue.
  2. Assess the company's ability to secure future financing.
  3. Analyze the trend in interest expense.

Glossary

Stockholders' Deficit
This occurs when a company's total liabilities exceed its total assets, resulting in a negative net worth for shareholders. (Indicates a negative equity position for QHSLab, Inc., highlighting financial distress.)
Going Concern
An accounting assumption that a business will continue to operate for the foreseeable future, typically at least 12 months from the reporting date. (The company's financial condition raises doubts about its ability to continue operating, requiring disclosure.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, QHSLab, Inc. saw a substantial 32% revenue increase to $1.99M, with gross profit rising to $1.32M. However, this top-line growth was overshadowed by a shift to a net loss of $99.16K from a net income of $28.35K in the prior year. Key drivers for this decline include a more than doubling of interest expense to $194.89K and a 97% surge in R&D costs to $369.17K. The company's financial precariousness is further emphasized by an increased stockholders' deficit of $610.91K.

Filing Stats: 4,409 words · 18 min read · ~15 pages · Grade level 15.6 · Accepted 2025-11-13 09:01:10

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS. 4 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 21 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES. 26

- OTHER INFORMATION

PART II - OTHER INFORMATION ITEM 6. EXHIBITS. 27 2 Cautionary Note Regarding Forward-Looking Statements This report contains forward-looking statements. Certain of the matters discussed herein concerning, among other items, our operations, cash flows, financial position and economic performance including, in particular, future sales, product demand, competition and the effect of economic conditions, include forward-looking statements. Forward-looking "anticipates," "intends," "plans," "believes," "estimates" and similar expressions. Although we believe that the forward-looking statements contained in this report are based upon reasonable assumptions, these statements and other projections contained herein expressing opinions about future outcomes and non-historical information, are subject to uncertainties and, therefore, there is no assurance that the outcomes expressed in these statements will be achieved. Investors are cautioned that forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the expectations expressed in forward-looking statements contained herein. Given these uncertainties, you should not place any reliance on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You are advised, however, to consult any additional disclosures we make in our reports filed with the Securities and Exchange Commission ("SEC"). 3 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS (unaudited) Condensed Consolidated Balance Sheets – September 30, 2025 (unaudited) and December 31, 2024 5 Condensed Consolid

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing